Jul. 15 at 5:48 PM
$ESPR The patents for Keytruda (pembrolizumab) are expected to expire in 2028. Specifically, the U.S. patents covering the intravenous formulation of Keytruda are set to expire on June 13, 2028. Keytruda sales account for roughly 40% of Merck revenue, and the company has been focused on the 2028 patent expiration for years.
The idea of combining an ACLY inhibitor with immunotherapy, particularly with Keytruda, is an active and promising area of preclinical research in oncology. There's a strong and evolving scientific rationale suggesting that an ACLY inhibitor could be used to improve the efficacy of Keytruda by modulating cancer cell metabolism and enhancing anti-tumor immune responses, particularly through the activation of innate immune pathways.
